Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | PAM | P19021 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8463255 | 0.87 | DGKA (0.43) | DGKAALDH1A1LMNATSHRDNM1 | |
| SCHEMBL16295140 | 0.87 | DGKA (0.43) | DGKAALDH1A1LMNATSHRDNM1 | |
| SCHEMBL8465959 | 0.87 | DGKA (0.43) | DGKAALDH1A1LMNATSHRDNM1 | |
| SCHEMBL8463526 | 0.87 | DGKA (0.43) | DGKAALDH1A1LMNATSHRDNM1 | |
| SCHEMBL134075 | 0.85 | TSHR (0.43) | DGKAALDH1A1LMNATSHRDNM1 | |
| SCHEMBL16294270 | 0.84 | TSHR (0.54) | DGKAALDH1A1LMNATSHR | |
| SCHEMBL16294179 | 0.84 | TSHR (0.54) | DGKAALDH1A1LMNATSHR | |
| SCHEMBL18038087 | 0.84 | TSHR (0.54) | DGKAALDH1A1LMNATSHR | |
| SCHEMBL7759649 | 0.82 | DGKA (0.38) | DGKAALDH1A1LMNATSHRDNM1 | |
| SCHEMBL13044430 | 0.81 | DGKA (0.50) | DGKAALDH1A1TSHRDNM1PAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595495-B2 | Methods of producing omega-hydroxylated fatty acid derivatives | GENOMATICA, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20250019731-A1 | Methods Of Producing Omega-Hydroxylated Fatty Acid Derivatives | AGAIN BIO APS (DK) | 2025-01-16 | — | — | US | disclosed |
| CN-105378486-B | Process for producing OMEGA-hydroxylated fatty acid derivatives | 基因组股份公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11981952-B2 | Methods of producing omega-hydroxylated fatty acid derivatives | GENOMATICA, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-20210189439-A1 | Multifunctional Fatty Acid Derivatives And Biosynthesis Thereof | GENOMATICA, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| EP-3810778-A1 | MULTIFUNCTIONAL FATTY ACID DERIVATIVES AND BIOSYNTHESIS THEREOF | Genomatica, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210071212-A1 | METHODS OF PRODUCING OMEGA-HYDROXYLATED FATTY ACID DERIVATIVES | GENOMATICA, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| EP-3745133-A1 | METHODS OF PRODUCING OMEGA-HYDROXYLATED FATTY ACID DERIVATIVES | Genomatica, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| US-10711288-B2 | Methods of producing omega-hydroxylated fatty acid derivatives | GENOMATICA, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| EP-2984490-B1 | METHODS OF PRODUCING OMEGA-HYDROXYLATED FATTY ACID DERIVATIVES | GENOMATICA INC (US) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019217226-A1 | MULTIFUNCTIONAL FATTY ACID DERIVATIVES AND BIOSYNTHESIS THEREOF | REG Life Sciences, LLC (US) | 2019-11-14 | — | — | WO | disclosed |
| US-20160130616-A1 | METHODS OF PRODUCING OMEGA-HYDROXYLATED FATTY ACID DERIVATIVES | AGAIN BIO APS (DK) | 2016-05-12 | — | — | US | disclosed |
| EP-2984490-A1 | METHODS OF PRODUCING OMEGA-HYDROXYLATED FATTY ACID DERIVATIVES | REG Life Sciences, LLC (US) | 2016-02-17 | — | — | EP | disclosed |
| WO-2014201474-A1 | METHODS OF PRODUCING OMEGA-HYDROXYLATED FATTY ACID DERIVATIVES | LS9, INC. (US) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595495-B2 | Methods of producing omega-hydroxylated fatty acid derivatives | CYP4F11, CYP2F1, CYP4Z1 | DGKA 982/4885ALDH1A1 327/4885LMNA 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.